ASCO GU 2018 interview: Pedro Barata oligoprogression

February 21, 2018

  • Share this post:

Pedro Barata, experimental therapeutics clinical fellow at the Taussig Cancer Institute Cleveland Clinic, explains the design and results of the trial he presented during the poster session. This retrospective study examined what the impact was of switching systemic treatment after radiosurgery for oligoprogressive, metastatic renal cell carcinoma.

Our ASCO GU coverage is editorially independent and financially made possible by Bayer and Janssen.

Related articles